Loading
CDKN2A (Cyclin-dependent kinase inhibitor 2A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Bladder & urothelial cancer and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein. Location: Cytoplasm; Nucleus (UniProt). Locus 9p21.3 (HGNC).
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Pancreatic ductal adenocarcinoma | 37-48% | Mutation or deep deletion (with CDKN2B and MTAP co-deletion) | cBioPortal: mutation in 546 of 2,336, 23.4%, and deep deletion in 359, 15.4%, in pdac_msk_2024; mutation 35 of 179, 19.6%, and deep deletion 52 of 183, 28.4%, in paad_tcga_pan_can_atlas_2018; mutation 6 and deep deletion 40 of 109, 42.2%, in paad_utsw_2015; mutation 93 of 395, 23.5%, and deep deletion 19 in pancreas_msk_2024; mutation 71 of 383, 18.5%, in paad_qcmg_uq_2016 (no copy-number profile); 29 of 140, 20.7%, in paad_cptac_2021. CDKN2B was co-deleted in 333 of 2,336 (pdac_msk_2024) and 50 of 183 (TCGA); MTAP deep deletion in 40 of 183, 21.9% (TCGA) and 34 of 109, 31.2% (UTSW), 51 of 2,336 on the MSK panel. | cBioPortal (TCGA) |
| Non-small-cell lung cancer | 26-41% | Deletion or mutation of CDKN2A, with RB1 loss | cBioPortal: CDKN2A deep deletion 128 of 487, 26.3%, plus mutation in 73 of 484, 15.1%, in lusc_tcga_pan_can_atlas_2018; deletion 47 of 178, 26.4%, plus mutation 31, 17.4%, in lusc_tcga_pub; mutation 17 of 108, 15.7%, in lusc_cptac_2021. RB1 is mutated in 31 of 484, 6.4%, with deep deletion in 16 of 487. The founding paper put CDKN2A and RB1 alteration together at 72% of tumours, counting epigenetic silencing and exon skipping as well as deletion and mutation (Cancer Genome Atlas Research Network 2012). | cBioPortal (TCGA) |
| Gallbladder cancer | 21% | Deletion or mutation | CDKN2A 21% (Giraldo 2022); CDKN2A/B 19% of 85 (Javle 2016); CDKN2A 9% of 376 Indian patients, significantly lower than Western and Asian cohorts (Suryavanshi 2025); cBioPortal gbc_mskcc_2022: CDKN2A deep deletion in 35 of 244, 14.3%, mutation in 26 of 244, 10.7%; CDKN2B deep deletion in 34 of 244, 13.9%. | doi.org |
| Non-small-cell lung cancer | 15-20% | Homozygous deletion and inactivating mutation | cBioPortal deep deletion: 358 of 2,422, 14.8%, in luad_mskcc_2023_met_organotropism; 86 of 511, 16.8%, in luad_tcga_pan_can_atlas_2018; 45 of 230, 19.6%, in luad_tcga_pub; 87 of 915, 9.5%, in lung_msk_2017, with mutation on top in 137, 25, 10 and 49 samples respectively. | cBioPortal (TCGA) |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"CDKN2A" OR ABSTRACT:"CDKN2A" OR TITLE:"cyclin dependent kinase inhibitor 2A" OR ABSTRACT:"cyclin dependent kinase inhibitor 2A" OR TITLE:"Cyclin-dependent kinase inhibitor 2A" OR ABSTRACT:"Cyclin-dependent kinase inhibitor 2A" OR TITLE:"CDK4I" OR ABSTRACT:"CDK4I" OR TITLE:"p16" OR ABSTRACT:"p16" OR TITLE:"INK4a" OR ABSTRACT:"INK4a") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CDKN2A, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/cdkn2a.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/cdkn2a.json. Licence CC BY-NC 4.0.